San Jose, CA, May 23, 2023

SAN JOSE, CALIFORNIA / ACCESSWIRE / May 23, 2023 / Earlier today Biomed Industries, Inc. issued a letter to the Board of Directors of Neoleukin Therapeutics, Inc. (NASDAQ: NLTX).

The letter described a proposal to acquire all of the company's common stock for $1.60 per share which represents an 80% premium on the average price of $0.88 over the past 10 days, in which one share of NLTX will be exchanged for $1.00 in cash plus $0.60, or 0.05 share of Biomed Industries. As NLTX has 42,818,346 outstanding shares, Biomed’s proposed offer has an enterprise value at $68.5 million.

Please visit the link of press release from AccessWire:

Biomed Industries, Inc. offers to acquire Neoleukin Therapeutics

About Biomed Industries, Inc.

Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer’s disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com

- CONTACT:

Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Michael Willis
Email: media@biomedind.com

For more news, please visit our News pages. More News

For further information about Biomed Industries, Inc., please contact us. Contact us